270: Your guide to Wegovy’s blockbuster heart study
The Readout Loud
00:00
Wigovi and Cardiovascular Health
Will this latest trial change that? It might. A lot of payers and employers have cited the lack of long-term data as reasons for not covering Wigovi or obesity treatments at large. Novo Nordisk hasn't been able to consistently manufacture enough of the drug to capitalize on its sudden celebrity.
Transcript
Play full episode
